Borchmann, P., Meerten, T. V., Bories, P., Dreger, P., Gopsca, L., Mutsaers, P., Edinger, M., Illes, A., Tresckow, B. V., Neumeister, P., Steiner, N., Jaeger, U., Moreno, A. T., Griškevičius, L., Iacoboni, G., Lemonnier, F., Doesum, J. V., Shah, N., Orentas, R., Miltenyi, S., Overstijns, T., Bürger, I., Zadoyan, G., Brillant, C., Heteren, P. V., Holtkamp, S., Vandenberghe, P. (2025). Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.. Blood. https://doi.org/10.1182/blood-2025-669